Audit: QRS - Sermorelin for Health & Longevity
Audit conducted on 06/08/2026 03:22 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 81 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated variable traces to a distinct ER passage: protocol cells to ER lines 351/359/371, time cells to ER line 406, benefit/risk tiers to the ER headings at lines 143-203 and 227-285, gates to ER lines 303-325, monitoring table to ER lines 432-444, qualitative items to ER lines 448-453. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious register is carried through: “Where it occurs” (time_3_sub), “In the trials that found them” (time_2_sub), “Other claims rest on thin evidence” and “decades untested” (at_a_glance). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retain absolute framing (pregnancy and breastfeeding, hypersensitivity, active malignancy); speculative benefits and risks stay in the Speculative tier; no ER hedge is dropped in a way that alters strength. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gates draw only from the ER Key Interactions & Contraindications section; the two “absolute contraindication to combined use” bullets (somatostatin analogues, recombinant growth hormone) are correctly placed under Contraindications rather than Key Interactions. No Benefit- or Risk-Modifying Factor is surfaced anywhere. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, citations, expert names or NCT identifiers appear. Every named agent (octreotide, somatropin, prednisone, dexamethasone, methimazole, glipizide, equine oestrogens, oestradiol, ipamorelin, CJC-1295, arginine, diphenhydramine, bethanechol) appears in the corresponding ER interaction bullet. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present in the populated content. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-weighted register matching the ER, including its scepticism (“Research doses that moved IGF-1 were higher”, “the claim with the weakest support”). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Biomarker targets and time-to-effect windows give actionable structure without hype or discouragement. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated descriptively (“Follows baseline IGF-1 against the age-adjusted range”), not prescribed. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or advisory verbs in the document’s own voice; the only advisory sentence is the fixed template footer disclaimer. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No instances of “recommend”, “advise”, “should”, “must”, or “consider” in the populated content. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the populated content. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to the Monitoring table, where the biomarker names are the measurement itself; the At-A-Glance and Protocol panels use plain wording. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate item, tier line, and table cell is a stripped-down phrase; no full sentences beyond the At-A-Glance and the sub-lines. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address in any populated span. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Presumes self-directed biomarker tracking, injection logistics, and titration against IGF-1 percentiles. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Nightly subcutaneous injection, two-hour fasting gap, and an 11-marker panel with a repeating cadence are presented without hedging on burden. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Functional biomarker targets (fasting insulin 2-5 mIU/L, HbA1c below 5.4%, apoB below 80 mg/dL) sit well inside conventional reference ranges, addressing an optimising reader. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The At-A-Glance pairs the confirmed biochemical effect with “Other claims rest on thin evidence” and “decades untested”, and the Risks card leads with tolerability rather than reassurance. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The term “anti-aging” does not appear; the title and header use “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Uses “subcutaneous”, “adverse events”, “injection-site reactions”, “impaired glucose tolerance”; the phrase “empty stomach” is carried verbatim from ER line 351. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings, gate headings, tier labels and column headers match the template byte-for-byte (lines 446, 483, 527, 559, 578, 599, 632, 636-638, 779). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 38 template variable names are present; the only additions are the repeated marker_#_* and qualitative_item_# instances the template provides as repeatable rows. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A structural diff against the template with variable contents masked shows no change to any non-variable markup, including the website="evidence_review", website="audit" and website="full_review" spans and the full stylesheet. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section feeding the QRS is empty — Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Therapeutic Protocol and Monitoring Protocol & Defining Success are all fully populated. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | The three protocol labels reproduce the ER bold labels verbatim: “The standard clinic protocol” (ER line 351), “Timing within the day” (ER line 359), “Baseline biomarkers as the dosing input” (ER line 371). Monitoring marker names reproduce the ER Biomarker column verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No protocol or monitoring label is altered. The time-to-effect labels derive from ER line 406, which supplies no bold sub-labels of its own. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | A character-class scan of the file returns no emoji; tiers are conveyed by bold text labels and the CSS palette. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed relative to the ER: magnitudes, mechanisms and citations stripped from Benefits and Risks; the Monitoring “Why” column reduced to single short clauses; qualitative items cut to their essentials. No section is carried over at ER length. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14, immediately after <!doctype html> on line 1 and before the next comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the preceding caption line is permitted. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the head or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration: "00:03" is quoted, which is required because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: sermorelin_2026-0806-0013_Opus_ER.md, matching the ER’s own filename frontmatter value. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0806-0249, correctly formatted. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: sermorelin_2026-0806-0013_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; only the colon-bearing duration value is quoted. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: Sermorelin for Health & Longevity - Quick Reference Sheet, matching the ER canonical_topic with the ampersand correctly encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: Sermorelin for Health & Longevity. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/06/2026, the correct MM/DD/YYYY rendering of 2026-0806-0249. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (lines 415-428) is structurally identical to the template; the ER’s alternate_names are not carried over and no badge, audit date or variant marker is present. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all four Conclusion paragraphs (ER lines 475-481): mechanism and preserved feedback, the confirmed biochemical and cognitive findings, the thinness of everything else, and the months-not-decades safety horizon. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “within normal rhythm and brakes” ← ER line 475; “Controlled studies … downstream messenger” and “reasonable evidence for better mental flexibility” ← ER line 477; “Other claims rest on thin evidence” ← ER line 477; “Safety across months is mild; decades untested” ← ER line 479. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms. IGF-1 is rendered as “its main downstream messenger” and GHRH as “the body’s own growth hormone-releasing signal”; “pituitary gland” is the ER’s own plain-language term. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values appear. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No percentages or numerical results; effects are described qualitatively. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All twelve items trace to that section — ten from the “Populations who should not use this intervention” bullet (ER line 325) and two from the bullets flagged “absolute contraindication to combined use” (ER lines 305 and 313). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Complete: all ten populations from ER line 325 plus the two absolute combined-use contraindications; nothing added, nothing omitted. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Twelve discrete <li> elements at lines 562-573. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No dashes carrying trailing clauses. The ER’s explanatory tail on the athlete item (“for whom the compound is prohibited at all times and for whom a therapeutic use exemption is very unlikely to be granted”) is correctly stripped to “Athletes under anti-doping testing”, and the USADA citation is dropped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “treated within five years”, “HbA1c above 8.0%”, “moderate-to-severe … (30+/hour)”, “Active proliferative” staging and the named example agents (octreotide, somatropin) are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in the contraindication content. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Twelve stop_items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items map one-to-one onto ER interaction bullets at lines 303, 307, 309, 311, 315, 317, 319, 321 and 323. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Exactly the nine non-absolute interaction bullets; the two absolute contraindications (somatostatin analogues, recombinant growth hormone) are correctly excluded here and carried in the Contraindications gate instead. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine discrete <li> elements at lines 581-589. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s dash-suffixed severity clauses (“— caution, reduced efficacy”, “— monitor, dose adjustment likely”, “— monitor, modest potentiation”, “— caution, mostly modest”) are all stripped, as is every mechanistic rationale. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every item retains a representative named agent or threshold — prednisone/dexamethasone, methimazole, glipizide, equine oestrogens/oestradiol, ipamorelin/CJC-1295, arginine, diphenhydramine, bethanechol — and the carbohydrate item retains the “within two hours” window from ER line 323. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in the interaction content; all parentheticals are already plain comma-separated drug lists. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Nine caution_items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol section (lines 351, 353, 359, 371). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose and route, timing within the day, and the input the dose is selected against — the three decisions required to execute the protocol. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section supplies twelve bullets, well above three, and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine cells populated: “100-300 mcg nightly” and the subcutaneous five-to-seven-nights detail plus the research-dose caveat (ER lines 351, 353); “Bedtime, empty stomach” with the two-hour gap and post-sleep-onset pulse (ER lines 351, 359, 323); “Baseline IGF-1, not weight” with the age-adjusted-range rationale (ER line 371). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Covers all three windows given in the ER “Time to effect” bullet (line 406): the 2-4 week IGF-1 shift, the 16-24 week cognitive and body-composition change, and the first-month subjective sleep change. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High tier (IGF-1 and growth hormone restoration) → Medium tier cognitive performance → the conflicted, age-attenuated Medium tier sleep effect. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are present in the ER and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine cells populated with ER-derived content, including “the first recheck in most protocols” and “a fair trial is at least four to six months” from ER line 406, and the older-subject attenuation from ER line 159. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (line 406), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All eleven benefit headings from ER lines 143-203 are represented in their ER tiers. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four variables present and populated (lines 529-552). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Reduced to condensed heading phrases; the ER’s Magnitude figures (70-107% growth hormone, 28% and 117% IGF-1, 7.4% body fat, p-values) and all citations are stripped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits variable. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All ten risk headings from ER lines 227-285 are represented in their ER tiers. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four variables present and populated (lines 601-626). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Reduced to condensed heading phrases; the ER’s Magnitude figures (68% vs 36% adverse events, 35% fasting insulin rise) and all citations are stripped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks variable; the ER’s inline glosses such as “(fluid swelling)” and “(joint pain)” are dropped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Every row derives from the ER Monitoring Protocol & Defining Success biomarker table (lines 432-444), with names and targets carried verbatim. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eleven ER rows are present in ER order: IGF-1, IGFBP-3, fasting insulin, fasting glucose, HbA1c, TSH with free T4, fasting lipid panel with apoB, hs-CRP, PSA in men over 45, complete blood count and comprehensive metabolic panel, body composition by DEXA. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 773 reproduces the schedule from ER lines 428 and 430: baseline before the first injection, IGF-1 at 4 weeks and after each dose change, full panel at 3 months then every 6 months, body composition every 6-12 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items derive from the qualitative marker list in the ER Monitoring Protocol & Defining Success section (lines 448-453). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six are present in ER order: sleep depth and continuity, mental flexibility and task-switching, daytime energy, exercise recovery, joint comfort, skin and hair texture. |
Issues 06/08/2026 03:22
Pass rate 100.00%. No issues found.
Issues 06/08/2026 03:11
- 4.5 — Sheet overruns the A4 page: At print width the document accumulates roughly twice the ~1,030 px A4 content budget — the Contraindications gate wraps to ~17 lines (QRS lines 562-573), Key Interactions to ~18 lines (QRS lines 581-589), and the Monitoring table plus cadence to ~530 px (QRS lines 642-774) — because the gate items, marker
Whycells, tier lists, protocolsubcells and qualitative items were left at ER-length phrasing instead of being condensed to the per-section budget.
Fixes 06/08/2026 03:11
- 4.5 — Condensed to the A4 budget: Tightened the two decision gates (12 contraindications and 9 interactions now sit on ~13 and ~11 rendered lines instead of ~17 and ~18, with all items, thresholds and time windows retained and drug lists trimmed to a leading example), shortened all eleven Monitoring
Whycells and the cadence line to single lines, and trimmed the three protocolsubcells, the BenefitsSpeculativetier and four qualitative items — no item, marker or qualifier was dropped.
Issues 06/08/2026 03:04
- 4.5 — Sheet overflows one A4 page: Cumulative rendered height of the populated blocks is roughly 2,200 px against ~1,040 px of usable A4 print height; the Monitoring “Why” cells (lines 661-810), the Qualitative Assessment items (lines 829-860) and the protocol/time sub-lines still carry near-verbatim ER sentences that were never condensed to a per-section budget.
- 9.5 — Insulin interaction drops named drugs: The “Insulin and glucose-lowering drugs” item (line 594) carries “(insulin, sulfonylureas)”, which restates its own label and omits the ER’s example drugs “glipizide, glyburide” (ER line 309).
Fixes 06/08/2026 03:04
- 4.5 — Sheet condensed toward the page budget: All eleven Monitoring “Why” cells, the monitoring cadence, the four longest Qualitative items, the three protocol sub-lines, the first time-to-effect sub-line and two contraindication items were rewritten in shorter form (e.g., “Detects growth hormone-driven insulin resistance well before glucose moves” → “Detects insulin resistance well before glucose moves”), cutting roughly a quarter of the rendered height while keeping every biomarker, contraindication and qualitative marker in place; the sheet remains longer than one A4 page because the completeness requirements of items 8.2, 14.2 and 15.2 forbid dropping entries.
- 9.5 — Insulin interaction example drugs: Replaced the self-referential parenthetical in the “Insulin and glucose-lowering drugs” gate item, from “(insulin, sulfonylureas)” to “(insulin, glipizide, glyburide)”, restoring the ER’s named example drugs.
Issues 06/08/2026 02:57
- 4.2 / 4.3 — Protocol cell label paraphrased: [action_1_label] at line 450 reads “Standard clinic dose”, but the ER bold label at line 351 is “The standard clinic protocol”; the label was paraphrased rather than carried over verbatim.
- 4.2 / 4.3 — Interaction label invented: The seventh [caution_items] entry at line 598 reads “Sedating antihistamine sleep aids (diphenhydramine, doxylamine)”, replacing the ER’s bold label “Over-the-counter medications” (line 319) with an invented one.
Fixes 06/08/2026 02:57
- 4.2 / 4.3 — Protocol cell label restored verbatim: [action_1_label] changed from “Standard clinic dose” to the ER’s bold label “The standard clinic protocol”.
- 4.2 / 4.3 — Interaction label restored verbatim: The seventh Key Interactions item changed from “Sedating antihistamine sleep aids (diphenhydramine, doxylamine)” to “Over-the-counter medications (diphenhydramine, doxylamine)”, matching the ER’s bold label while keeping the named example drugs.